Biogen Idec, Galapagos in scleroderma target discovery deal

Biogen Idec Inc. (NASDAQ:BIIB) partnered with the BioFocus service division of Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) to identify and validate novel targets in scleroderma. Under the three-year deal, BioFocus will use its SilenceSelect gene knock-down technology and human skin models to deliver new assays and identify disease-modifying targets for Biogen Idec. BioFocus is eligible for up to $31 million under the deal, including an undisclosed upfront payment. ...